| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | 207,8 k € | -3.3% | 214,9 k € | -17.5% | 260,4 k € | +0.2% | 259,8 k € | -7.9% | 282,2 k € | +17.3% | 240,6 k € | |||||||
| Gross margin | 190,0 k € | +35.2% | 140,6 k € | -3.0% | 144,9 k € | -22.3% | 186,7 k € | +40.1% | 133,3 k € | +9.6% | 121,6 k € | -6.5% | 130,0 k € | +21.6% | 106,9 k € | -40.9% | 180,7 k € | +0.7% | 179,4 k € | -10.0% | 199,4 k € | +3.6% | 192,5 k € | |
| EBITDA | 188,7 k € | +34.6% | 140,2 k € | -3.0% | 144,6 k € | -22.4% | 186,3 k € | +39.8% | 133,2 k € | +9.6% | 121,6 k € | -6.5% | 130,0 k € | +22.8% | 105,9 k € | -41.4% | 180,7 k € | +0.8% | 179,3 k € | -8.8% | 196,5 k € | +2.2% | 192,2 k € | |
| Operating profit | 182,4 k € | +35.6% | 134,5 k € | -3.9% | 140,0 k € | -24.5% | 185,6 k € | +46.2% | 126,9 k € | +20.5% | 105,3 k € | -2.7% | 108,3 k € | +36.2% | 79,5 k € | -49.9% | 158,7 k € | -2.3% | 162,3 k € | -12.3% | 185,1 k € | -1.1% | 187,2 k € | |
| Profit/loss | 117,8 k € | +38.3% | 85,2 k € | -5.3% | 90,0 k € | -26.5% | 122,5 k € | +10.2% | 111,1 k € | +37.9% | 80,6 k € | +15.0% | 70,1 k € | +28.6% | 54,5 k € | -48.3% | 105,4 k € | +28.5% | 82,0 k € | -37.4% | 131,0 k € | +6.2% | 123,4 k € | |
| Equity | 587,7 k € | -12.3% | 669,9 k € | +14.6% | 584,7 k € | +18.2% | 494,7 k € | +32.9% | 372,2 k € | +42.6% | 261,1 k € | -16.2% | 311,6 k € | -17.9% | 379,5 k € | +19.0% | 318,9 k € | -8.6% | 348,9 k € | +30.7% | 266,8 k € | +96.5% | 135,8 k € | |
| Total assets | 1,4 M € | +14.0% | 1,3 M € | +13.0% | 1,1 M € | +13.0% | 988,3 k € | +33.4% | 740,6 k € | +7.0% | 692,2 k € | +1.8% | 680,3 k € | +7.7% | 631,8 k € | +14.4% | 552,4 k € | +36.9% | 403,5 k € | +26.5% | 319,1 k € | +59.3% | 200,3 k € | |
| Cash | 428,9 k € | +34.0% | 320,0 k € | +52.5% | 209,8 k € | -56.2% | 478,6 k € | -24.8% | 636,3 k € | +23.2% | 516,6 k € | +22.9% | 420,4 k € | +8.6% | 387,2 k € | +27.4% | 303,9 k € | +58.3% | 192,0 k € | +67.3% | 114,8 k € | -26.9% | 157,1 k € | |
| Debts | 822,7 k € | +46.4% | 562,1 k € | +11.4% | 504,4 k € | +5.4% | 478,4 k € | +33.5% | 358,5 k € | -15.1% | 422,3 k € | +18.2% | 357,2 k € | +44.5% | 247,2 k € | +5.8% | 233,5 k € | +327.0% | 54,7 k € | +4.6% | 52,3 k € | -18.9% | 64,5 k € | |
Source: Belgian Official Gazette
Private limited company · Gembloux · incorporated on 20/12/2013
Private limited company profitable and well capitalised. Cash position rising (+34.0%).
Acceptable counterparty for a moderate engagement. Require 2 fiscal years of detailed accounts before any significant exposure. The abridged model hides revenue.
Biocytom GBX is a Private limited company incorporated in 2013. Its main activity is: Other human health activities. Its registered office is in Gembloux.
Key indicators
7-day free trial, no credit card required.
7-day free trial, no credit card required.
7-day free trial, no credit card required.